Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

95 results about "Nonsteroidal Antiinflammatory Drugs/NSAIDs" patented technology

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class that reduce pain, decrease fever, prevent blood clots and, in higher doses, decrease inflammation. Side effects depend on the specific drug, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack and kidney disease.

Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug

InactiveUS20050249806A1Preventing gastric acid related disorderReduce riskBiocideSenses disorderNonsteroidal Antiinflammatory Drugs/NSAIDsBuffering agent
Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid related disorders and treating inflammatory disorders, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug.
Owner:SANTARUS

Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors

The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and / or inflammation while reducing gastrointestinal side effects.
Owner:HORIZON PHARMA USA

NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery

The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.
Owner:IDEA AG

Dimethicone-containing sustained release injection formulation

InactiveUS20070053943A1Prevention and treatment of problemBiocidePharmaceutical delivery mechanismDrugAnalgesic agents
A sustained release formulation by using dimeticone as the dispersion medium, which includes active ingredient (e.g., drugs against parasites, insecticides, NSAIDs, antibiotics, sex hormone like agents or oily soluble vitamins) and dimeticone as the medium. Suitable stabilizer, antioxidant, local analgesics and material for sustained release may be added. The formulation is bio-compatible, stable and injectable.
Owner:WANG YUWAN +2

Topical anesthetic formulation

The topical medicament gel formulation of the present invention includes an anesthetic, an anti-microbial, an oxidant, a nutrient, a diuretic, an opioid, an anti-emetic, an anti-seizure drug, and a non-steroidal anti-inflammatory drug (NSAID), USP in a molecular, as opposed to a salt form, as the active ingredient. Additional constituents illustratively include a skin penetration enhancer and a gelling agent. This invention deals with problems commonly associated with topical application of local medicaments such as: slow onset of action; need for occlusion; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the medicament and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.
Owner:WEPFER SCOTT

Zonisamide and nsaid nanoparticulate formulations

The present invention is directed to compositions comprising zonisamide, or a salt or derivative thereof, and at least one nanoparticulate NSAID. The zonisamide and NSAID combination preferably includes nanoparticulate NSAID particles of the composition with an effective average particle size of less than about 2000 nm. The zonisamide and NSAID combination is useful in the treatment of migraine and acute migraine pain and related conditions.
Owner:ELAN PHRMA INT LTD

Medicament for treatment of nocturia

A method for preventive and / or therapeutic treatment of nocturia, which comprises the step of administering to a mammal including a human in need of such treatment a preventively and / or therapeutically effective amount of a nonsteroidal anti-inflammatory drug such as loxoprofen.
Owner:SANKYO CO LTD

R-NSAID esters and their use

The present invention concerns esters of R-enantiomers of a non-steroidal anti-inflammatory drug, which is substantially free from the S-enantiomer. The compounds of the invention may be used in treating a disease or illness in a mammal. To this end, a composition comprising a compound mentioned above, or a pharmaceutically acceptable salt thereof where salt formation occurs, is administered to the mammal in an amount sufficient to elicit a chemopreventative effect or a chemoprotective effect or a therapeutic effect or a prophylactic effect.
Owner:ENCORE PHARMA

Amide derivatives for antiangiogenic and/or antitumorigenic use

InactiveUS6207700B1Generate efficientlyMinimizes and obviates irritationBiocideAntipyreticStereochemistryCancer
A method of treating animals having cancer by administration of secondary amide derivatives of various COOH-containing drugs, such as COOH-containing NSAIDs, for instance, indomethacin.
Owner:VANDERBILT UNIV

Bile preparations for gastrointestinal disorders

InactiveUS20060188530A1Impair its compositionHigh strengthBiocideDispersion deliveryDiseaseDrug compound
The present disclosure relates to methods and compositions to offset, ameliorate and / or alleviate one or more unwanted and / or adverse gastrointestinal effects. For example, in some embodiments, the present disclosure relates to compositions that include a bile acid, a carbohydrate and / or a pharmaceutical compound, wherein the pharmaceutical is associated with an adverse gastrointestinal effect in a subject (e.g., mammal or human). Non-limiting examples of pharmaceutical compounds may include a nonsteroidal anti-inflammatory drug, a gastric irritating drug (e.g., an antibiotic, an adrenal cortocoid steroid and an anti-cancer drug) and combinations thereof. The disclosure further relates to methods of ameliorating or eliminating at least one adverse gastrointestinal effects of a composition, comprising administering to a subject an aqueous solution comprising a bile acid and a carbohydrate.
Owner:YOO SEO HONG

Method for treating acute or chronic pain

The present invention concerns the use of compounds of the Formula (I) for treating different types of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and / or secondary inflammatory osteoarthritic pain. The compounds show an antinociceptive profile and differ from classical analgesics like opioids and non-steroidal anti-inflammatory drugs NSAIDs) and are useful as specific analgesics.
Owner:UCB SA

Therapeutic methods using prostaglandin EP4 agonist components

Methods are provided directed to adminstering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to affliction with a disease or condition selected from an esophageal ulcer, alcohol gastrophathy, a duodenal ulcer, non-steroidal anti-inflammatory drug-induced gastropathy, non-steroidal anti-inflammatory drug-induced enteropathy and intestinal ischemia. Such administration results in treating or preventing the disease or condition.
Owner:ALLERGAN INC

Methods of Making Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastointestinal Tract and Providing Enhanced Therapeuitc Activity

A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and / or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Methods of Treating Inflammation with Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastrointestinal Tract and Providing Enhanced Therapeutic Activity

A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and / or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection

InactiveUS7132452B2Fasten skin recoveryPromote recoveryPowder deliveryBiocideComplete remissionTolmetin
The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain / inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and / or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.
Owner:YUNG SHIN PHARMACEUTICALS INDUSTRIAL CO LTD

Oil-based nsaid compositions and methods for making and using same

A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and / or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Anti-inflammatory pharmaceutical composition

The present invention provides an orally administrable capsule comprising at least two mini-tablets, or at least two mini-capsules, or a combination of at least a mini-tablet and a mini-capsule, wherein one of said mini-tablet or mini-capsule comprises a nonsteroidal anti-inflammatory drug and the other mini-tablet or mini-capsule comprises a prostaglandin.
Owner:DR REDDYS LAB LTD +1

Compositions comprising thylakoids useful in the modulation of inflammation process

ActiveUS20050048148A1Improve responseModulate the inflammatory processCosmetic preparationsBiocideInflammation ProcessGlucocorticoid
This invention relates to the use of a thylakoid extract that is preferably stabilized and activable for treating inflammation. Different types of cell or tissue targets and inflammatory stimuli have been used to evaluate the performance of the extract, which, in all cases successfully modulate inflammation through a balance of pro / anti-inflammatory cytokines. Compositions comprising the extract and other anti-inflammatory agents, namely glucocorticoids or NSAIDs are further disclosed and claimed.
Owner:GRP SANTE DEVONIAN INC

Method and compositions for treatment of chronic neuropathic pain

Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and / or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors.
Owner:APKARIAN TECH

Thermo-sensitive in-situ gel for articular cavity injection and preparation method thereof

The invention mainly provides thermo-sensitive in-situ gel for articular cavity injection and a preparation method thereof. The gel is prepared from a drug-loaded biodegradable high-molecular polymer in a physical crosslinking way. The high-molecular polymer is prepared by connecting hyaluronic acid and a temperature-sensitive material through chemical bonds; when the temperature is lower than the body temperature, the drug can be loaded or dispersed into the polymer to form a nanogel suspension; and the temperature of an articular cavity injection part is raised to the body temperature, the preparation is converted from the nano suspension to the in-situ gel. The gel provided by the invention is free of chemical crosslinking, high in safety and capable of taking the synergic treatment effects of a nonsteroidal anti-inflammatory drug and the hyaluronic acid, reducing the toxic and side effects and improving the compliance of a patient.
Owner:JIANGNAN UNIV

Ibuprofen-based compound, preparation method, use, and formulation of the same

Disclosed are compounds based on ibuprofen, their preparation methods, uses and pharmaceutical preparation. The compounds have structures shown as formula (1), wherein, m, n are integers and fulfill the requirements of 0≦n≦6, 0≦m≦6, respectively. The preparation methods for the compounds based on ibuprofen are as follows: contacting and reacting 2-(4-isobutyl-phenyl) propionic acid to have contact reaction with a solution of an organic acid ester in the presence of a catalyst under substitution reaction conditions The present compounds can be used to prepare nonsteroidal anti-inflammatory drugs. The preparation can be preparation of fat emulsion, liposome, and dried emulsion and so on.
Owner:HEILONGJIANG BAOQINGLONG BIOTECH

Pharmaceutical composition for anti-inflammation ease-pain

The invention provides an anti-inflammatory and pain-killing medical composition; chondroitin sulfate and a non-steroidal anti-inflammatory agent are used as active ingredients and mixed with a medical carrier to form the composition. Non-steroidal anti-inflammatory agent includes but not confines in diclofenac sodium (potassium), naprosyn and Lornoxicam; the composition exists in forms of squirt, freeze-dried powder and large-capacity transfusion for intravenous medication of a human body. The composition can be applied to symptomatic treatments of various febrile illnesses, various arthritises and inflammatory rheumatic diseases, soft tissue rheumatisms, neuralgia, arthralgia and pains, wounds relevant to degenerative diseases of spines, or postoperative pains.
Owner:FUKANGREN BIO PHARMA

Combinations for use in increasing the potency of a substrate for multidrug resistance related protein

A combination of an agent which is a substrate for multidrug resistance related protein (MRP) and an inhibitor of MRP which is a nonsteroidal anti-inflammatory drug (NSAID) or a structural analogue thereof for simultaneous, sequential or separate use for increasing the potency of the substrate. The substrates include anti-cancer drugs and transition metal complexes. The combinations can be used to overcome the resistance to MRP substrates exhibited in many conditions, such as resistance to chemotherapy where patients have developed resistance, especially as a result of MRP over-expression to their chemotherapy.
Owner:DUBLIN CITY UNIVERSITY +1

Composition for transdermal absorption and formulation comprising a polymeric matrix formed therefrom

The inventive composition for transdermal absorption characterized by comprising a nonsteroidal anti-inflammatory drug as an active ingredient together with an alkali metal-containing alcohol derivative as a solubilizing agent for the active ingredient comprises a high concentration of the active ingredient while using only a small amount of the solvent, and a transdermal absorption formulation comprising a polymeric matrix formed from the composition is capable of maximizing the skin absorption of the active ingredient with minimal skin irritation.
Owner:AMOREPACIFIC CORP

Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone

The presence of the ancient anti-inflammatory peptide α-melanocyte stimulating hormone (α-MSH [1-13], SYSMEHFRWGKPV) in barrier organs such as gut and skin suggests a role in the nonspecific (innate) host defense system. α-MSH and other amino acid sequences derived from α-MSH were determined to have antimicrobial influences, including against two major and representative cutaneous and mucosal pathogens: Staphylococcus aureus and Candida albicans. C-MSH peptides had antimicrobial effects against S. aureus and significantly reversed the enhancing effect of urokinase on S. aureus colony formation. α-MSH and other amino acid sequences reduced C. albicans viability and germination. α-MSH peptides also enhanced C. albicans killing by human neutrophils. The antimicrobial agent is selected from the group consisting of one or more peptides including the amino acid sequence KPV, one or more peptides including the amino acid sequence MEHFRWG, or a biologically functional equivalent of any of the foregoing. The most effective of the peptides were those bearing the C-terminal amino acid sequence of α-MSH, i.e., α-MSH (1-13), (6-13), and (11-13). The α-MSH “core” sequence (4-10), important for melanotropic effects, was also effective but significantly less potent. Antimicrobial influences of α-MSH peptides could be mediated by their well-known capacity to increase cellular cAMP; this messenger was significantly augmented in peptide-treated yeast. α-MSH has potent anti-inflammatory effects and is expected to be useful for treatment of inflammation in human and veterinary disorders. Reduced killing of pathogens is a detrimental consequence of therapy with corticosteroids and nonsteroidal anti-inflammatory drugs during infection. Therefore, anti-inflammatory agents based on α-MSH peptides that do not reduce microbial killing, but rather enhance it, would be very useful. The antimicrobial effects of these α-MSH peptides occurred over a broad range of concentrations including the physiological (picomolar) range.
Owner:ZENGEN

Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially throug

The application describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug; the third component, alternatively, can take the role of a drug. The application further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The application finally reveals suitable methods and favourable conditions for carrier manufacturing and application. The application also describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium.
Owner:IDEA AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products